Toray Develops Porous Fiber to Adsorb Pathogenic Substances in Intractable Diseases
Toray Industries has developed a technology to precisely control the pore size of PMMA porous fibers, enabling the selective adsorption of large-molecule pathogenic substances. This innovation offers a new blood purification treatment option for autoimmune, cardiovascular, neurodegenerative diseases, and cancer.
📋 Article Processing Timeline
- 📰 Published: March 27, 2026 at 00:12
- 🔍 Collected: March 28, 2026 at 21:59 (45h 47m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 02:01 (412h 2m after Collected)
Toray Industries has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers in a range from several nm to approximately 1,000 nm. This advancement allows for the selective adsorption and removal of large-molecule pathogenic substances—such as autoantibodies, lipoproteins, and exosomes—which were previously difficult to eliminate. The technology aims to provide a new blood purification treatment option for intractable diseases like autoimmune disorders, cardiovascular diseases, neurodegenerative conditions, and cancer, where traditional drug or surgical therapies are insufficient.
FAQ
What diseases does this technology treat?
It targets intractable diseases such as autoimmune disorders, cardiovascular diseases, neurodegenerative conditions, and cancer.